Usana Health Sciences (USNA) revenue and earnings history
Usana Health Sciences reported revenue of $925M for fiscal 2025 (year ended Jan 3, 2026), +8.3% on the year before, and net income of $10.8M.
Over 9 years, from fiscal 2016 to fiscal 2025, revenue grew at a compound rate of −0.9% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Jan 3, 2026 | $925M+8.3% | $37.4M | $10.8M | $22.3M | $13.8M | $8.53M | $13.8M | $27.5M | — | $158M | — | 10-K |
| 2024ended Dec 28, 2024 |
The latest quarter, insider trades and fund moves: Usana Health Sciences (USNA) on OQRO.
Common questions
What was Usana Health Sciences's revenue in fiscal 2025?
$925M for the year ended Jan 3, 2026, as reported in its 10-K filed Mar 16, 2026. That is +8.3% on fiscal 2024 ($855M).
How fast has Usana Health Sciences's revenue grown?
From $1.01B in fiscal 2016 to $925M in fiscal 2025: a compound annual growth rate of −0.9% over 9 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Usana Health Sciences tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
